<DOC>
	<DOCNO>NCT01389271</DOCNO>
	<brief_summary>This open-label , uncontrolled , prospective long-term observation Specific Drug treatment patient pulmonary hypertension 4 year . 160 patient primary ( idiopathic familial ) pulmonary hypertension ( PH ) pulmonary arterial hypertension ( PAH ) due scleroderma New York Heart Association ( NYHA ) functional class exercise capacity , define class III IV plan enroll . Efficacy , safety tolerability drug survival patient observe .</brief_summary>
	<brief_title>Inhaled Iloprost Treatment Patients With Pulmonary Hypertension 4 Years</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients pulmonary hypertension treat inhaled iloprost old 18 year old . Primary ( idiopathic familial ) pulmonary hypertension ( PH ) New York Heart Association ( NYHA ) functional class exercise capacity , define class III IV . Pulmonary arterial hypertension ( PAH ) due scleroderma New York Heart Association ( NYHA ) functional class exercise capacity , define class III IV . Patients sign write informed consent . Severe coronary heart disease unstable angina ; Myocardial infarction within last six month ; Decompensated cardiac failure close medical supervision ; Severe arrhythmias ; Cerebrovascular event ( e.g . transient ischaemic attack , stroke ) within last 3 month . Pulmonary hypertension due venous occlusive disease . Congenital acquire valvular defect clinically relevant myocardial function disorder related pulmonary hypertension . Pregnancy lactation Age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Inhaled iloprost</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Survival</keyword>
	<keyword>NYHA class III IV</keyword>
</DOC>